Select Publications
Journal articles
1997, 'Transmission of human immunodeficiency virus type-1 resistant to nevirapine and zidovudine', Journal of Infectious Diseases, 175, pp. 1502 - 1506
,1996, 'How HIV leads to hypersensitivity reactions', Medical Journal of Australia, 164, pp. 227 - 229, http://dx.doi.org/10.5694/j.1326-5377.1996.tb94146.x
,1996, 'Managing HIV. Part 3: Mechanisms of disease. 3.5 How HIV leads to hypersensitivity reactions.', Med J Aust, 164, pp. 227 - 229, https://www.ncbi.nlm.nih.gov/pubmed/8604194
,1996, 'Managing HIV. Part 2: Phases of disease. 2.1 Primary HIV infection.', Med J Aust, 164, pp. 105 - 106, https://www.ncbi.nlm.nih.gov/pubmed/8569558
,1996, 'Primary HIV infection', MEDICAL JOURNAL OF AUSTRALIA, 164, pp. 105 - 106, http://dx.doi.org/10.5694/j.1326-5377.1996.tb101365.x
,1996, 'Clinical treatment.', AIDS (London, England), 10 Suppl A, http://dx.doi.org/10.1097/00002030-199601001-00018
,1996, 'Diabetes mellitus associated with pentamidine use in HIV-infected patients.', The Medical journal of Australia, 165, pp. 587 - 588, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138654.x
,1996, 'Factors associated with stress responses in staff caring for patients with cystic fibrosis', Irish Journal of Psychology, 17, pp. 241 - 250, http://dx.doi.org/10.1080/3033910.1996.10558105
,1996, 'Managing HIV: 2.1 Primary HIV infection', Medical Journal of Australia, 164, pp. 105 - 106, http://dx.doi.org/10.5694/j.1326-5377.1996.tb101365.x
,1996, 'A controller trial of nevirapine plus zidovudine versis zidovudine aklone in p24 antigenaemic HIV infected patients', AIDS, 10, pp. 635 - 641
,1996, 'Alterations in the immune response of HIV-infected subjects treated with an HIV specific protease inhibitor, ritonavir', Journal of Infectious Diseases, 173, pp. 321 - 329
,1996, 'CD8+ lymphocyte responses to antiretroviral therapy of HIV infection', Journal of acquired immune deficiency syndrome and human retrovirology, 13, pp. 320 - 326
,1996, 'Current clinical experience with nevirapine for HIV infection', Advances in Experimental Medicine and Biology, pp. 299 - 304
,1996, 'Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions:evidence for viral compartmentalisation and selection during sexual transmission', Journal of Virology, pp. 3098 - 3107
,1996, 'HIV protease inhibitors', AIDS, 10, pp. 151 - 157
,1996, 'Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.', J Infect Dis, 174, pp. 195 - 198, http://dx.doi.org/10.1093/infdis/174.1.195
,1995, 'A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of hiv-1 protease', New England Journal of Medicine, 333, pp. 1528 - 1534, http://dx.doi.org/10.1056/NEJM199512073332303
,1995, 'PREFERENTIAL TRANSMISSION OF CELL-ASSOCIATED VIRUS AND EVIDENCE FOR SELECTION OF HIV-1 IN THE NEW HOST FOLLOWING SEXUAL CONTACT', JOURNAL OF CELLULAR BIOCHEMISTRY, pp. 230 - 230, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995QT86500787&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1995, 'Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor', Journal of Virology, 69, pp. 1324 - 1327, http://dx.doi.org/10.1128/jvi.69.2.1324-1327.1995
,1995, 'If it's the virus, why aren't we measuring it?', The Medical journal of Australia, 163, pp. 508 - 509, http://dx.doi.org/10.5694/j.1326-5377.1995.tb124712.x
,1995, 'Pathogenesis and management of HIV-associated drug hypersensitivity.', AIDS clinical review, pp. 65 - 97
,1995, 'Safety, pharmacokinetics, and antiviral activity of ritonavir, an inhibitor of HIV-1 protease', JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 10, pp. 75 - 75, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995UC13800076&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1995, 'A controlled trial of zidovudine in primary human immunodeficiency virus infection', New England Journal of Medicine, pp. 408 - 413
,1995, 'Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes', AIDS, pp. 561 - 566
,1994, 'Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients', AIDS, 8, pp. 333 - 337, http://dx.doi.org/10.1097/00002030-199403000-00006
,1994, 'Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection', Clinical and Experimental Immunology, 97, pp. 260 - 265, http://dx.doi.org/10.1111/j.1365-2249.1994.tb06078.x
,1994, 'In HIV‐infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine', Reviews in Medical Virology, 4, pp. 5 - 8, http://dx.doi.org/10.1002/rmv.1980040104
,1993, 'Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response [1]', AIDS, 7, pp. 127 - 128, http://dx.doi.org/10.1097/00002030-199301000-00020
,1993, 'Allergy and desensitization to zidovudine in patients with acquired immunodeficency syndrome (AIDS)', The Journal of Allergy and Clinical Immunology, 91, pp. 683 - 685, http://dx.doi.org/10.1016/0091-6749(93)90276-L
,1993, 'Attitudes to euthanasia and assisted suicide in a group of homosexual men with advanced HIV disease', Journal of Acquired Immune Deficiency Syndromes, 6, pp. 1069 - 1070
,1993, 'CD4+ lymphocytopenia in HIV-seronegative homosexual men [4]', AIDS, 7, pp. 1272 - 1273
,1993, 'Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with pneumocystis carinii pneumonia and AIDS', Journal of Infectious Diseases, 167, pp. 180 - 185, http://dx.doi.org/10.1093/infdis/167.1.180
,1993, 'Cotrimoxazole prophylaxis for toxoplasmosis [3]', Annals of Internal Medicine, 118, pp. 395, http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00018
,1993, 'Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients', AIDS, 7, pp. 65 - 71
,1993, 'In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV', Clinical and Experimental Immunology, 94, pp. 21 - 25, http://dx.doi.org/10.1111/j.1365-2249.1993.tb05971.x
,1993, 'Patterns of multiple-drug hypersensitivities in HIV-infected patients [4]', AIDS, 7, pp. 1532 - 1533, http://dx.doi.org/10.1097/00002030-199311000-00023
,1993, 'Prophylaxis of opportunistic infections in patients with HIV infection', Journal of Acquired Immune Deficiency Syndromes, 6, pp. S56 - S60
,1993, 'Recommendations for prophylaxis against pneumocystis carinii pneumonia for persons infected with human', Journal of Acquired Immune Deficiency Syndromes, 6, pp. 46 - 55
,1993, 'Update on reverse transcriptase inhibitors in HIV disease', Israel Journal of Medical Sciences, 29, pp. 26 - 30
,1992, 'Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS', Annals of Internal Medicine, 117, pp. 106 - 111
,1992, 'Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS', AIDS, 6, pp. 165 - 171
,1991, 'Allergic manifestations of human immunodeficiency virus (HIV) infection', Journal of Clinical Immunology, 11, pp. 55 - 64, http://dx.doi.org/10.1007/BF00917741
,1990, 'Drug hypersensitivity', Medical Journal of Australia, 153, pp. 631, http://dx.doi.org/10.5694/j.1326-5377.1990.tb126299.x
,Conference Papers
2017, 'Failure of antiretroviral therapy (ART) in Australian adults is mainly due to ART toxicity', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27395
,2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27403
,2017, 'Socioeconomic and psychosocial factors are associated with suboptimal outcomes in HIV-infected adults: a case-control analysis', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27399
,2016, 'Concomitant medication use in ART-experienced Australian adults: data from the PAART study', in Antiviral Therapy, International Medical Press, New York City, USA, presented at The 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, New York City, USA, 12 September 2016 - 13 September 2016
,2014, 'Changes in bone mineral density and markers of bone turnover over 96 weeks after switching from tenofovir to raltegravir', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, PA, Philadelphia, pp. A35 - A35, presented at 16th International Workshop on Co-Morbidities and Adverse Drug Reaction in HIV, PA, Philadelphia, 06 October 2014 - 08 October 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354600300036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'LOWER FAT MASS AND LOWER BONE FORMATION PREDICT GREATER BONE LOSS WITH TENOFOVIR IN HIV-INFECTED ADULTS', in OSTEOPOROSIS INTERNATIONAL, SPRINGER LONDON LTD, AUSTRALIA, Gold Coast, pp. S614 - S615, presented at IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, AUSTRALIA, Gold Coast, 04 September 2011 - 08 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000309258200234&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A28 - A29, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,